Company: TXG
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001770787-25-000013
Chunk: 5

Company: 10x Genomics, Inc.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 8
Chunk 5
---
,868 Net loss— — — (182,627)— (182,627)Other comprehensive loss— — — — (64)(64)Balance as of December 31, 2024122,291,837 $2 $2,177,672 $(1,467,047)$(493)$710,134 

The accompanying notes are an integral part of these consolidated financial statements

82

10x Genomics, Inc.

Consolidated Statements of Cash Flows

(In thousands)

Year Ended December 31,202420232022Operating activities:Net loss$(182,627)$(255,099)$(166,000)Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Stock-based compensation expense140,749 166,950 136,848 Depreciation and amortization35,879 35,512 25,368 Lease and asset impairment charges3,054 9,845 — Amortization of right-of-use assets7,829 8,107 7,638 Realized loss on marketable securities3 1,718 — Other523 427 1,957 Changes in operating assets and liabilities:Accounts receivable26,951 (10,613)(18,948)Inventory(9,777)7,871 (21,192)Prepaid expenses and other current assets(1,901)(2,429)(4,495)Other noncurrent assets(1,084)(678)925 Accounts payable(3,354)(6,017)5,858 Accrued compensation and other related benefits3,654 (2,637)1,114 Deferred revenue11,209 10,932 3,350 Accrued expenses and other current liabilities(12,736)28,301 3,336 Operating lease liability(12,484)(8,671)(6,423)Other noncurrent liabilities776 1,284 (2,942)Net cash provided by (used in) operating activities6,664 (15,197)(33,606)Investing activities:Proceeds from sales of marketable securities3,856 100,191 49,117 Proceeds from maturities of marketable securities25,782 82,825 18,528 Purchases of property and equipment(12,393)(48,601)(